In an effort to focus on growth and innovation, Israeli generic pharmaceutical company Teva Pharmaceutical Industries (NYSE: TEVA) will divest its active pharmaceutical ingredient (API) business.
The company, known as TAPI, is a major player in the small molecule API industry, with approximately 4,300 employees worldwide.
TAPI serves more than 1,000 customers globally, including biotechnology and pharmaceutical companies, with a portfolio of approximately 350 products.
Growth strategy
Tifa said…
This article is available to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the brightest minds in pharma and biotechnology for a week. If you are already a registered user please log in. If your trial period has expired, you can sign up here.
Try before you buy
• All the news that moves the needle in pharma and biotechnology.
• Exclusive features, podcasts, interviews, data analyzes and commentary from our global network of life sciences reporters.
• Get the Pharma Letter daily newsletter, free forever.
Become a subscriber
• Unrestricted access to industry-leading news, commentary and analysis in pharmaceutical and biotechnology.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulation, patents, legal and executive appointments, commercial strategy and financial results.
• Daily report on key events in the field of pharmaceuticals and biotechnology.
• In-depth monthly briefings on board appointments and mergers and acquisitions news.
• Choose from a cost-effective annual package or a flexible monthly subscription.
